Last reviewed · How we verify
P03277
At a glance
| Generic name | P03277 |
|---|---|
| Also known as | Gadopiclenol, gadopiclenol |
| Sponsor | Guerbet |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Cardiac Safety Evaluation of P03277 (PHASE1)
- Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI (PHASE2)
- Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis (PHASE2)
- P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) (PHASE2)
- Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions (PHASE1, PHASE2)
- MR Quality + Diagnostic Performance for CHC Diagnosis - Gadoxetic Acid, Gadoteric Acid and P03277 Comparison
- Pharmacokinetics, Dialysability and Safety of P03277 in Healthy Volunteers and in Patients With Impaired Renal Function (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P03277 CI brief — competitive landscape report
- P03277 updates RSS · CI watch RSS
- Guerbet portfolio CI